Core Viewpoint - The company reported a significant increase in revenue but also a substantial net loss for the fiscal year 2025, indicating challenges in profitability despite growth in sales [1]. Group 1: Financial Performance - The company achieved an operating revenue of 113 million yuan, representing a year-on-year growth of 40.13% [1]. - The net profit attributable to shareholders was -17.3 million yuan, indicating an increase in losses compared to the previous year [1]. Group 2: Product Development and Regulatory Status - The company completed the enrollment of participants for the Phase III clinical trial of its quadrivalent influenza virus split vaccine for children and has finished the vaccination process [1]. - The application for market production of the trivalent influenza virus split vaccine has been accepted, with various regulatory checks completed, awaiting further review by the CDE [1]. Group 3: Inventory and Asset Management - Due to equipment failures and material discrepancies, the company decided not to sell certain in-process and finished products, adhering to a cautious approach [2]. - The quadrivalent influenza virus split vaccine has a shelf life of 12 months, and any unused vaccines at the end of the flu season must be disposed of according to legal requirements [2]. - The company has made provisions for asset impairment and inventory write-offs totaling approximately 41.9996 million yuan, based on market research and historical return rates [2].

Core Viewpoint - The company anticipates a net loss of 160 million to 180 million yuan for 2025, primarily due to increased R&D expenses and asset impairment provisions [2][4] Group 1: Financial Performance - The company has announced a projected net loss of 160 million to 180 million yuan for 2025, representing an increase in losses year-on-year [2] - The loss is attributed to R&D investments, asset impairment provisions, and inventory write-offs totaling approximately 41.99 million yuan [2][4] - Investors are advised to monitor the upcoming annual report for audited financial details [2] Group 2: Product Development Progress - The Phase III clinical trial for the quadrivalent influenza virus split vaccine (for children) has completed participant enrollment and vaccination, with serum currently under inspection by the China Food and Drug Administration [3] - The application for market production of the trivalent influenza virus split vaccine has been accepted, with registration inspections and standard reviews completed, awaiting further evaluation from the National Medical Products Administration [3] - These developments may significantly impact the company's future product line expansion [3]